| Display title | Chemistry:Moxonidine |
| Default sort key | Moxonidine |
| Page length (in bytes) | 10,381 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 802577 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Steve2012 |
| Date of page creation | 19:47, 5 February 2024 |
| Latest editor | imported>Steve2012 |
| Date of latest edit | 19:47, 5 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Moxonidine (INN) is a new-generation alpha-2/imidazoline receptor agonist antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. It may have a role when thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or have failed to control... |
